An Unusual Cause of Generalized Insulin Edema and Truncal Neuropathy
Nicola Tufton a, b, Simon Coppack a, Bobby Huda a

Abstract

Insulin edema and acute neuropathy are rare side effects of insulin initiation or rapid improvement in glycemic control. Both conditions occurring simultaneously are very rare and there are no previous data on truncal neuropathy as a dominant feature. A 35-year-old lady, who presented with an infected, necrotic fourth finger and was admitted for debridement and antibiotics, developed diabetic ketoacidosis. Past medical history included latent autoimmune disease of adults. She was non-compliant with medication and had experienced significant weight loss (37 kg; body mass index (BMI) 15.1 kg/m²). She was glutamic acid decarboxylase antibody positive, with poor glycemic control (HbA1c 133 mmol/mol (14.3%)). She was treated with intravenous and then subcutaneous insulin. From day 3, she developed significant pitting edema to her umbilicus. She was treated with furosemide 40 mg once daily and fluid restriction. Other causes of edema were excluded. Peak weight gain was 5 kg and edema resolved 2 weeks later. She also developed a painful sensory neuropathy over dermatomes T12-L2 on day 5, which persisted for several months before resolution. Magnetic resonance imaging was normal and nerve conduction studies showed generalized diabetic sensorimotor neuropathy. This is the first report of edema and truncal neuropathy developing secondary to insulin initiation and a rapid improvement in glycemic control. Our case was particularly susceptible due to poor glycemic control, low bodyweight, hepatic dysfunction and low serum albumin. This case highlights the importance of being aware of the rare complications of insulin therapy, particularly in susceptible patients.

Keywords: Type 1 diabetes; Insulin edema; Truncal neuropathy; Painful neuropathy; Insulin side effects

Introduction

Insulin edema and acute neuropathy are rare side effects of insulin initiation or rapid improvement in glycemic control. Both conditions occurring simultaneously in the same individual are very rare and there are no previous data on truncal neuropathy as a dominant feature. Similarities between our case and another recently reported case suggest risk factors for both complications are similar, which may indicate a shared underlying pathophysiological mechanism. Mild insulin edema is a recognized complication of insulin initiation, and probably under reported, but there are very few reported cases of generalized edema.

We report for the first time, a case of generalized edema and truncal neuropathy, occurring simultaneously after insulin initiation, with numerous similarities to another recently reported case of generalized edema and generalized neuropathic pain following initiation of insulin pump.

Case Report

A 35-year-old lady presented with a painful discolouration of her right fourth finger and was admitted under the plastic surgical team for debridement and washout of her necrotic finger (she refused amputation) and antibiotic treatment for hand cellulitis. In Australia, 5 years previously, she had been diagnosed with diabetes mellitus and subsequently latent autoimmune diabetes (LADA), as she was strongly positive for glutamic acid decarboxylase (GAD) antibody (> 2,000,000 units/L). She refused insulin treatment and therefore was managed with glimepiride 80 mg twice daily and lifestyle intervention. She was lost to follow-up after this initial diagnosis. She did not smoke or drink alcohol, and had no relevant family history. Glycemic control was poor, with HbA1c prior to admission at 133 mmol/mol (14.3%), and she had lost a significant amount of weight (18 kg) in the preceding 3 months.

On admission, she was underweight (37.5 kg, BMI 15.1 kg/m²), with a necrotic right fourth digit, but physical examination revealed no other specific abnormalities. She had normal renal and liver function (eGFR 149 mL/min, albumin 41 g/L), and raised C-reactive protein (107 mg/L) and white blood count (WBC 11.8 × 10⁹/L). Arterial blood gas showed acidosis (pH 7.27, HCO₃ 13 mEq/L), glucose 24 mmol/L and
The true incidence of insulin edema is unknown and is probably under reported [1]. A review of the edematogenic properties of insulin describes clinical risk factors that increase the risk of developing edema. These include being aged 20 - 40 years, type 1 diabetes, poor glycemic control (including both hypoglycaemia episodes and following treatment of DKA), poor nutritional status, low body weight, new-onset diabetes and higher doses of insulin therapy [1]. Our case met almost all of these high risk criteria as did another recently reported similar case, of generalized edema and neuropathy occurring after initiation of insulin pump therapy [2]. In that case the acute neuropathy was generalized, rather than the rarer truncal distribution.

The mechanisms of insulin edema are unknown [1], and several theories have been postulated. These include increased microvascular permeability [3], direct triggering of vascular endothelial growth factors [4], as well as a direct action of insulin on the renal tubules causing anti-natriuresis [5]. Associations with malnutrition may be secondary to unmasking of thiamine deficiency by insulin, and lactate and pyruvate accumulation produce peripheral vasodilation and edema [1]. There is also a proposed genetic predisposition with the 3243 mitochondrial tRNA^Lys(UUR)^ mutation [6].

Takahiro et al suggest a link between hepatic dysfunction and a predisposition to developing insulin edema [5]. Acute hepatic decompensation is associated with transient insulin resistance and hyperinsulinemia, due to impaired glucose utilization in peripheral tissue and decreased insulin degradation and clearance. Once established, both refractory hyperglycemia and body water retention are promoted by intensifying sodium reabsorption in the renal tubules, increasing vascular permeability causing hypoalbuminemia and therefore reducing oncotic pressure [5]. It is possible that this contributed to the development of insulin-induced edema in our patient and transient derangement of liver function has been reported in other cases [2, 7].

Many resolve with conservative management along with reduction in insulin dosing or dietary salt restriction [1, 2, 7, 8]. If there is evidence of malnutrition, thiamine supplementation should be initiated [1]. Diuretic use with furosemide 40 mg once daily, bumetanide 1 mg per day or spironolactone 100 mg per day have been tried with variable success [1, 2, 9, 10]. There have been a few reported successfully treated cases of initiating vasoactive drugs, such as ephedrine 15 mg per day divided over three doses, in severe edema resistant to diuretics [1, 9, 10].

Treatment-induced neuropathy is characterized by a reversible acute, severe painful, peripheral nerve degeneration and autonomic dysfunction after intensive glycemic control [11], which can occur at proximal sites including the trunk [12]. There is very little literature on acute truncal neuropathy. An older case series reported that symptoms were mainly sensory, asymmetric, occurring in a root distribution with an equal sex distribution and good prognosis. Most spontaneously recovered over 3 months [8].

There have been reported associations between acute severe neuropathy and significant weight loss, both intentionally (dieting or withholding of insulin) and unintentionally [11]; this was particularly relevant in our patient.

**Conclusion**

Both insulin-induced edema and acute painful neuropathy are recognized, albeit rare side effects of initiation or increasing insulin therapy, with resultant rapid correction of glycemic
control. There are numerous similarities between our case and one previously reported [2], both with regard to risk factors (similar preceding time course of diabetes, no underlying cardiac, renal or hepatic disease, poor glycemic control demonstrated by high HbA1c, underweight) and clinical course of disease. Whilst rare these two side effects occurring simultaneously, suggest a possible similar underlying pathophysiology.

**Funding**

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

**Declaration**

The authors have none to declare.

**References**